Alginate microbeads are complement compatible, in contrast to polycation containing microcapsules, as revealed in a human whole blood model

Acta Biomaterialia

Volumn 7, Issue 6, 2011, Pages 2566-2578

  Rokstad, Anne Mari ^a   Brekke, Ole Lars ^b   Steinkjer, Bjørg ^a   Ryan, Liv ^a   Kolláriková, Gabriela ^c   Strand, Berit L ^a   Skjåk Bræk, Gudmund ^a   Lacík, Igor ^c   Espevik, Terje ^a   Mollnes, Tom Eirik ^b,d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORDLAND HOSPITAL   (Norway)

^c POLYMER INSTITUTE   (Slovakia)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alginate; Biocompatibility; Complement; Microbead; Microcapsule

Indexed keywords

AMINO ACIDS; BIOCOMPATIBILITY; BLOOD; CELL ADHESION; CHEMICAL ACTIVATION; PHASE LOCKED LOOPS; SODIUM ALGINATE; SULFUR COMPOUNDS;

ANAPHYLATOXINS; BLOOD MODELS; COMPLEMENT; ELEVATED LEVEL; LEUCOCYTES; MICROBEADS; MICROCAPSULES; POLY-L-LYSINE; POLYCATIONS; WHOLE BLOOD;

MICROSTRUCTURE;

9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)GUANINE; ALGINIC ACID; ANAPHYLATOXIN; BIOMATERIAL; CD11B ANTIGEN; CELLULOSE SULFATE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C5A; LEPIRUDIN; MICROSPHERE; POLYCATION; POLYLYSINE;

ARTICLE; BLOOD; DRUG DOSAGE FORM; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; MICROBEAD; MICROCAPSULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; UPREGULATION;

EID: 79955595431     PISSN: 17427061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actbio.2011.03.011     Document Type: Article

References (39)

1. De Vos P, Bucko M, Gemeiner P, Navratil M, Svitel J, Faas M, et al. Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials 2009;30:2559-70.
2. Read TA, Stensvaag V, Vindenes H, Ulvestad E, Bjerkvig R, Thorsen F. Cells encapsulated in alginate: a potential system for delivery of recombinant proteins to malignant brain tumours. Int J Dev Neurosci 1999;17:653-63. (Pubitemid 29421850)
3. Nilsson B, Korsgren O, Lambris JD, Ekdahl KN. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol 2010;31:32-8.
4. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, et al. Essential role of the C5a receptor in E. Coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002;100:1869-77.
5. Andersson J, Ekdahl KN, Larsson R, Nilsson UR, Nilsson B. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunol 2002;168:5786-91. (Pubitemid 34556164)
6. Mollnes TE, Lea T, Harboe M. Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol 1984;20:157-66. (Pubitemid 14061737)
7. Toda M, Kitazawa T, Hirata I, Hirano Y, Iwata H. Complement activation on surfaces carrying amino groups. Biomaterials 2008;29:407-17. (Pubitemid 350100797)
8. Andersson J, Ekdahl KN, Lambris JD, Nilsson B. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials 2005;26:1477-85. (Pubitemid 39441380)
9. Arima Y, Kawagoe M, Furuta M, Toda M, Iwata H. Effect of swelling of poly(vinyl alcohol) layers on complement activation. Biomaterials 2010;31:6926-33.
10. 2+ microbeads: in vitro and in vivo function. Artif Cells Blood Substit Immobil Biotechnol 2008;36:403-20.
11. 2+-alginate microbeads in diabetic immunocompetent mice. Unpublished work.
12. Wang T, Lacik I, Brissova M, Anilkumar AV, Prokop A, Hunkeler D, et al. An encapsulation system for the immunoisolation of pancreatic islets. Nat Biotechnol 1997;15:358-62. (Pubitemid 27150252)
13. Wang T, Adcock J, Kuhtreiber W, Qiang D, Salleng KJ, Trenary I, et al. Successful allotransplantation of encapsulated islets in pancreatectomized canines for diabetic management without the use of immunosuppression. Transplantation 2008;85:331-7. (Pubitemid 351322755)
14. Lacik I, Brissova M, Anilkumar AV, Powers AC, Wang T. New capsule with tailored properties for the encapsulation of living cells. J Biomed Mater Res 1998;39:52-60. (Pubitemid 128751757)
15. King A, Sandler S, Andersson A. The effect of host factors and capsule composition on the cellular overgrowth on implanted alginate capsules. J Biomed Mater Res 2001;57:374-83. (Pubitemid 32885269)
16. King A, Strand B, Rokstad AM, Kulseng B, Andersson A, Skjak-Braek G, et al. Improvement of the biocompatibility of alginate/poly-L-lysine/alginate microcapsules by the use of epimerized alginate as a coating. J Biomed Mater Res A 2003;64:533-9. (Pubitemid 37522494)
17. Strand BL, Ryan TL, In't VP, Kulseng B, Rokstad AM, Skjak-Brek G, et al. Poly-L-lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant 2001;10:263-75.
18. Safley SA, Cui H, Cauffiel S, Tucker-Burden C, Weber CJ. Biocompatibility and immune acceptance of adult porcine islets transplanted intraperitoneally in diabetic NOD mice in calcium alginate poly-L-lysine microcapsules versus barium alginate microcapsules without poly-L-lysine. J Diabetes Sci Technol 2008;2:760-7.
19. Mollnes TE, Redl H, Hogasen K, Bengtsson A, Garred P, Speilberg L, et al. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993;91:295-300.
20. Strand BL, Morch YA, Espevik T, Skjak-Braek G. Visualization of alginate-poly-L-lysine-alginate microcapsules by confocal laser scanning microscopy. Biotechnol Bioeng 2003;82:386-94. (Pubitemid 36505876)
21. De Vos P, De Haan BJ, Wolters GH, Strubbe JH, van Schilfgaarde R. Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets. Diabetologia 1997;40:262-70. (Pubitemid 27096549)
22. Anilkumar AV, Lacik I, Wang TG. A novel reactor for making uniform capsules. Biotechnol Bioeng 2001;75:581-9. (Pubitemid 33134992)
23. Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Lambris JD, Videm V, et al. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg 2004;77:932-41. (Pubitemid 38271064)
24. 2+ on alginate microbeads. Biomacromolecules 2006;7:1471-80.
25. Gros P, Milder FJ, Janssen BJ. Complement driven by conformational changes. Nat Rev Immunol 2008;8:48-58.
26. Tam SK, Dusseault J, Polizu S, Menard M, Halle JP, Yahia L. Physicochemical model of alginate-poly-L-lysine microcapsules defined at the micrometric/nanometric scale using ATR-FTIR, XPS, and ToF-SIMS. Biomaterials 2005;26:6950-61. (Pubitemid 41095519)
27. McNally AK, Anderson JM. Complement C3 participation in monocyte adhesion to different surfaces. Proc Natl Acad Sci USA 1994;91:10119-23. (Pubitemid 24311960)
28. Wright SD, Weitz JI, Huang AJ, Levin SM, Silverstein SC, Loike JD. Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci USA 1988;85:7734-8.
29. Rinder CS, Smith MJ, Rinder HM, Cortright DN, Brodbeck RM, Krause JE, et al. Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation. Ann Thorac Surg 2007;83:146-52. (Pubitemid 44920421)
30. Schwartz-Albiez R, Adams Y, Von der Lieth CW, Mischnick P, Andrews KT, Kirschfink M. Regioselectively modified sulfated cellulose as prospective drug for treatment of malaria tropica. Glycoconj J 2007;24:57-65. (Pubitemid 44935065)
31. Eisen V, Loveday C. Effect of cellulose sulphate on serum complement. Br J Pharmacol 1970;39:831-3.
32. Eisen V, Loveday C. In vivo effects of cellulose sulphate on plasma kininogen, complement and inflammation. Br J Pharmacol 1971;42:383-91.
33. Toso C, Mathe Z, Morel P, Oberholzer J, Bosco D, Sainz-Vidal D, et al. Effect of microcapsule composition and short-term immunosuppression on intraportal biocompatibility. Cell Transplant 2005;14:159-67. (Pubitemid 40604959)
34. De Vos P, De Haan B, van Schilfgaarde R. Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules. Biomaterials 1997;18:273-8. (Pubitemid 27064804)
35. Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Mollnes TE. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition. Ann Thorac Surg 2004;78:38-44.
36. Lappegard KT, Bergseth G, Riesenfeld J, Pharo A, Magotti P, Lambris JD, et al. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A 2008;87:129-35.
37. Lappegard KT, Christiansen D, Pharo A, Thorgersen EB, Hellerud BC, Lindstad J, et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci USA 2009;106:15861-6.
38. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE. Lambris JD: Complement and coagulation: strangers or partners in crime? Trends Immunol 2007;28:184-92.
39. Akalin HE, Fisher KA, Laleli Y. Caglar S: Bactericidal activity of ascitic fluid in patients with nephrotic syndrome. Eur J Clin Invest 1985;15:138-40. (Pubitemid 15027132)